Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The medicines used to treat HIV can suppress but cannot kill all the virus in the body. A small amount of virus remains at low levels in the part of the blood called the plasma. It is of crucial importance to identify the source of the residual virus in patients receiving antiretroviral therapy. The purpose of this study is to investigate whether the source of low level plasma virus is from latent (old) infection or ongoing (new) infection. MK-0518 is a investigational drug, which means that is not yet FDA approved, that works in a different way to other anti-HIV medicines to help kill the virus. We hypothesize that addition of MK-0518 to a stable anti-HIV regimen will reduce the viral load further in patients with undetectable plasma virus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

NCT00515827

HIV Infections

COMPLETED PHASE2

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

NCT00377065

HIV Infections

APPROVED_FOR_MARKETING

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

NCT01245101

HIV

TERMINATED PHASE4

Integrase Inhibitor (MK-0518) Viral Decay

NCT00520897

HIV Infections

COMPLETED PHASE2

Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

NCT01814722

Human Immunodeficiency Virus

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a non-randomized, non-comparative, single center trial of antiretroviral therapy intensification using the investigational integrase inhibitor MK-0518 and an investigational viral load assay to measure response to additional antiviral therapy. Eighteen patients will receive open-label MK-0518 400 mg P.O. every 12 hours for 28 days in addition to their prescribed antiretroviral therapy. Patients will take their doses of MK-0518 without regard to food. The study will enroll patients on antiretroviral therapy regimens with Cluster of Differentiation 4 (CD4) counts greater than 200 cells/ul, HIV-1 RNA levels \<50 copies RNA/ml plasma using a commercial assay(conventional Amplicor) and with detectable plasma virus (viral loads ≥ 1 copies RNA/ml plasma, Single copy assay, "SCA"). Acceptable antiretroviral regimens will include those on Nucleoside reverse transcriptase inhibitors ("NRTIs") + protease inhibitor (PI)I, NRTIs + non-nucleoside reverse transcriptase inhibitors (NNRTIs), + PI, or NRTIs + NNRTI-containing regimens. Patients cannot have prior evidence of resistance to antiretroviral drugs. Patients will be screened for intensification by history, physical exam, and laboratory evaluations (see below). Patients who are eligible and who agree to participate will intensify their antiretroviral therapy for 28 days with MK-0518 400 mg by mouth twice a day. During the 28- day drug addition, patients will have samples drawn for SCA assay at entry and on days 7, 14, 21, and 28 (+/- 1 d), with the last day of intensification as day 28. Patients will have additional phlebotomy after intensification on days 29, 30, 35, 42, 49 and 58 (+/- 1 day). The intensification period is followed by a post- intensification period to determine whether removal of the drug resulted in viral RNA changes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Raltegravir intensification

Patients will be administered raltegravir 400 mg orally twice daily in addition to antiretroviral therapy

Group Type EXPERIMENTAL

Raltegravir (MK-0518)

Intervention Type DRUG

Antiretroviral drug intensification with Raltegravir (MK0518) 400mg orally every 12 hours for 28 days in addition to the prescribed antiretroviral therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Raltegravir (MK-0518)

Antiretroviral drug intensification with Raltegravir (MK0518) 400mg orally every 12 hours for 28 days in addition to the prescribed antiretroviral therapy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MK-0518

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-1 infection documented by positive HIV-1 ELISA and positive
* Male or female at least 18 years of age, and able to provide written, informed consent
* Current antiretroviral therapy with Department of Health and Human Services (DHHS)-recommended regimen: NRTIs + PI, NRTIs + NNRTI + PI, or NRTIs + NNRTI
* Screening CD4 \> 200 cells/ µl and CD4%\> 14%; does not require prophylaxis for opportunistic infections
* Receiving a stable antiretroviral regimen for 4 months prior to screening
* HIV-1 RNA level below the limit of detection by commercial HIV-1 RNA determination assays for at least 12 months prior to screening.
* HIV RNA ≥ 0.6 copy RNA/ml plasma by SCA(single copy assay)
* Hgb ≥ 9.0 mg/dl, absolute neutrophil count \> 1000/mm3, platelet count \> 100,000/mm3
* Alkaline phosphatase, Aspartate transaminase (AST) and Alanine aminotransferase (ALT) \< 2.0 x upper limit of normal
* Willing to take MK-0518 for 28 days in addition to ongoing antiretroviral therapy
* Be considered clinically stable, in the opinion of the investigator, at the time of entry into the study; i.e., clinical status and all chronic medications should be unchanged for at least two weeks prior to entry.

Exclusion Criteria

* Prior participation in an MK-0518 or other integrase inhibitor trial
* Requires prohibited medications noted in the protocol
* Requires cytotoxic agents including hydroxyurea or vaccinations during the study period
* Received immunosuppressive therapy including steroids within one month prior to treatment in this study
* Used any investigational agents within a month prior to treatment in this study
* Documented resistance to any drug in each of the 4 classes of licensed antiretroviral agents by genotype or phenotype
* Any febrile illness (T\>38oC) in the 3 weeks prior to enrollment
* Any vaccination in the 6 weeks prior to enrollment
* Diagnosis of acute hepatitis due to any cause
* Positive Hepatitis B surface antigen
* Severe renal insufficiency defined as a calculated creatinine clearance at time of screening as \< 30 ml/min, based on the Cockcroft-Gault equation.
* Condition (including but not limited to alcohol or other substance use) which in the opinion of the investigator would interfere with patient compliance or safety

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No